Tags

Type your tag names separated by a space and hit enter

Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection?
Curr Eye Res. 2020 Jul 07 [Online ahead of print]CE

Abstract

PURPOSE

The aim of this study was to evaluate the effect of vitreous reflux (VR) on the short-term effect of intravitreal ranibizumab injection.

MATERIALS AND METHODS

The study included 181 eyes of 81 age-related macular degeneration (AMD) and 100 diabetic macular edema (DME) patients. Treatment response was evaluated by measuring central macular thickness (CMT) as well as 1 mm and 3 mm central macular thicknesses (MT1 and MT3). Patients were grouped as; Group 1: no VR, Group 2: <3 mm VR, and Group 3: >3 mm VR according to conjunctival bleb diameters. The data were analyzed using variance, correlation and regression analyses.

RESULTS

In AMD patients, reduction of CMT values following the treatment were 88.3 ± 110.6 µm in Group 1, 85.6 ± 158.7 µm in Group 2, and 93.1 ± 92.2 µm in Group 3. Likewise, in DME patients, it was 82.4 ± 88.4 µm, 72.9 ± 109.9 µm, and 73.7 ± 113.7 µm, respectively. Reduction of MT1 values after the treatment were 47.4 ± 72.6 µm, 36.0 ± 131.9 µm, and 36.7 ± 114.4 µm in AMD patients, and 33.3 ± 72.5 µm, 36.6 ± 90.2 µm, and 46.9 ± 83.4 µm in DME patients. In all comparisons among groups of VR, macular thickness (MT) change did not exhibit significant difference following an intravitreal ranibizumab treatment (p > .05).

CONCLUSION

We found that the increase in VR amount did not adversely affect the decrease in MT after intravitreal ranibizumab treatment in AMD and DME patients.

Authors+Show Affiliations

Department of Ophthalmology, Aksaray Training and Research Hospital, Aksaray University , Aksaray, Turkey.Department of Ophthalmology, Faculty of Medicine, Abant Izzet Baysal University , Bolu, Turkey.Department of Ophthalmology, Faculty of Medicine, Abant Izzet Baysal University , Bolu, Turkey.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32635750

Citation

Uyar, Enes, et al. "Can Vitreous Reflux Affect the Short-Term Treatment Response After Intravitreal Ranibizumab Injection?" Current Eye Research, 2020, pp. 1-7.
Uyar E, Ulaş F, Alkan Y. Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection? Curr Eye Res. 2020.
Uyar, E., Ulaş, F., & Alkan, Y. (2020). Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection? Current Eye Research, 1-7. https://doi.org/10.1080/02713683.2020.1789664
Uyar E, Ulaş F, Alkan Y. Can Vitreous Reflux Affect the Short-Term Treatment Response After Intravitreal Ranibizumab Injection. Curr Eye Res. 2020 Jul 7;1-7. PubMed PMID: 32635750.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection? AU - Uyar,Enes, AU - Ulaş,Fatih, AU - Alkan,Yunus, Y1 - 2020/07/07/ PY - 2020/7/9/entrez KW - Age-related macular degeneration KW - diabetic macular edema KW - intravitreal ranibizumab KW - macular thickness KW - treatment response KW - vitreous reflux SP - 1 EP - 7 JF - Current eye research JO - Curr. Eye Res. N2 - PURPOSE: The aim of this study was to evaluate the effect of vitreous reflux (VR) on the short-term effect of intravitreal ranibizumab injection. MATERIALS AND METHODS: The study included 181 eyes of 81 age-related macular degeneration (AMD) and 100 diabetic macular edema (DME) patients. Treatment response was evaluated by measuring central macular thickness (CMT) as well as 1 mm and 3 mm central macular thicknesses (MT1 and MT3). Patients were grouped as; Group 1: no VR, Group 2: <3 mm VR, and Group 3: >3 mm VR according to conjunctival bleb diameters. The data were analyzed using variance, correlation and regression analyses. RESULTS: In AMD patients, reduction of CMT values following the treatment were 88.3 ± 110.6 µm in Group 1, 85.6 ± 158.7 µm in Group 2, and 93.1 ± 92.2 µm in Group 3. Likewise, in DME patients, it was 82.4 ± 88.4 µm, 72.9 ± 109.9 µm, and 73.7 ± 113.7 µm, respectively. Reduction of MT1 values after the treatment were 47.4 ± 72.6 µm, 36.0 ± 131.9 µm, and 36.7 ± 114.4 µm in AMD patients, and 33.3 ± 72.5 µm, 36.6 ± 90.2 µm, and 46.9 ± 83.4 µm in DME patients. In all comparisons among groups of VR, macular thickness (MT) change did not exhibit significant difference following an intravitreal ranibizumab treatment (p > .05). CONCLUSION: We found that the increase in VR amount did not adversely affect the decrease in MT after intravitreal ranibizumab treatment in AMD and DME patients. SN - 1460-2202 UR - https://www.unboundmedicine.com/medline/citation/32635750/Can_Vitreous_Reflux_Affect_The_Short-Term_Treatment_Response_After_Intravitreal_Ranibizumab_Injection L2 - http://www.tandfonline.com/doi/full/10.1080/02713683.2020.1789664 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.